Azaperone

DB11376

small molecule investigational vet_approved

Deskripsi

Azaperone is a pyridinylpiperazine and butyrophenone agent that is capable of eliciting neuroleptic sedative and antiemetic effects. It is subsequently employed predominantly as a veterinary tranquilizer and mainly for pigs and elephants. At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.

Struktur Molekul 2D

Berat 327.403
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

747 Data
Buprenorphine Azaperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Hydrocodone Azaperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Magnesium sulfate The therapeutic efficacy of Azaperone can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Azaperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Azaperone may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Mirtazapine Azaperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Orphenadrine Azaperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Azaperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Rotigotine Azaperone may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Azaperone.
Suvorexant Azaperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Thalidomide Azaperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Azaperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Azaperone may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Azaperone is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Azaperone is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Azaperone.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Azaperone.
Sulpiride Azaperone may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Azaperone.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Azaperone.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Azaperone.
Mequitazine Azaperone may increase the arrhythmogenic activities of Mequitazine.
Sodium oxybate Azaperone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ethanol Azaperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Azaperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.
Zimelidine The risk or severity of adverse effects can be increased when Azaperone is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Azaperone is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Azaperone is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Azaperone is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Azaperone is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Azaperone is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Azaperone is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Azaperone is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Azaperone is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Azaperone is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Azaperone is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Azaperone is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Azaperone is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Azaperone is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Azaperone.
Indalpine The risk or severity of adverse effects can be increased when Azaperone is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Azaperone is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Azaperone is combined with Alaproclate.
Carbidopa The therapeutic efficacy of Carbidopa can be decreased when used in combination with Azaperone.
Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Azaperone.
Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Azaperone.
Procyclidine The therapeutic efficacy of Procyclidine can be decreased when used in combination with Azaperone.
Profenamine The therapeutic efficacy of Profenamine can be decreased when used in combination with Azaperone.
Lisuride The therapeutic efficacy of Lisuride can be decreased when used in combination with Azaperone.
Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Azaperone.
Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Azaperone.
Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Azaperone.
Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Azaperone.
Pergolide The therapeutic efficacy of Pergolide can be decreased when used in combination with Azaperone.
3,5-Dinitrocatechol The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Azaperone.
Etilevodopa The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Azaperone.
Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Azaperone.
Dexetimide The therapeutic efficacy of Dexetimide can be decreased when used in combination with Azaperone.
Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Azaperone.
Piribedil The therapeutic efficacy of Piribedil can be decreased when used in combination with Azaperone.
Benserazide The therapeutic efficacy of Benserazide can be decreased when used in combination with Azaperone.
Tropatepine The therapeutic efficacy of Tropatepine can be decreased when used in combination with Azaperone.
Melevodopa The therapeutic efficacy of Melevodopa can be decreased when used in combination with Azaperone.
Dihydroergocryptine The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Azaperone.
Phenglutarimide The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Azaperone.
Mazaticol The therapeutic efficacy of Mazaticol can be decreased when used in combination with Azaperone.
Etybenzatropine The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Azaperone.
Budipine The therapeutic efficacy of Budipine can be decreased when used in combination with Azaperone.
Bornaprine The therapeutic efficacy of Bornaprine can be decreased when used in combination with Azaperone.
Etanautine The therapeutic efficacy of Etanautine can be decreased when used in combination with Azaperone.
Dexpramipexole The therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Azaperone.
Cabergoline The therapeutic efficacy of Cabergoline can be decreased when used in combination with Azaperone.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Azaperone.
Rasagiline The therapeutic efficacy of Rasagiline can be decreased when used in combination with Azaperone.
Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Azaperone.
Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Azaperone.
Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Azaperone.
Ifenprodil The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Azaperone.
Progabide The therapeutic efficacy of Progabide can be decreased when used in combination with Azaperone.
Selegiline The therapeutic efficacy of Selegiline can be decreased when used in combination with Azaperone.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Azaperone.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Azaperone.
Zopiclone The risk or severity of adverse effects can be increased when Azaperone is combined with Zopiclone.
Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Azaperone.
Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Azaperone.
Meperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Azaperone.
Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Azaperone.
Mazindol The risk or severity of adverse effects can be increased when Mazindol is combined with Azaperone.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Azaperone.
Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Azaperone.

Target Protein

D(3) dopamine receptor DRD3
D(2) dopamine receptor DRD2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 925952
    Baeyens W, De Moerloose P, De Taeye L: Fluorescence characteristics of azaperone and of an azaperone mononitrogen oxide. J Pharm Sci. 1977 Dec;66(12):1787-9.
  • PMID: 420685
    Gerbig T: Azaperone (Stresnil) as a sedative for dogs. Berl Munch Tierarztl Wochenschr. 1979 Jan 1;92(1):12-5.
  • PMID: 1217501
    Borka L, Valdimarsdottir S: The polymorphism of azaperone and clotrimazole. Acta Pharm Suec. 1975;12(5-6):479-84.
  • PMID: 5519354
    Lang E: Use of azaperone on the pig. Berl Munch Tierarztl Wochenschr. 1970 Apr 15;83(8):141-3.
  • PMID: 4786114
    Allsup FC, Hillidge CJ, Lees P, Serrano L: Azaperone-metomidate anaesthesia in the horse. Vet Rec. 1973 Nov 3;93(18):498.
  • PMID: 3411917
    Olson ME, Renchko P: Azaperone and azaperone-ketamine as a neuroleptic sedative and anesthetic in rats and mice. Lab Anim Sci. 1988 Jun;38(3):299-304.
  • PMID: 19239653
    Heinonen ML, Raekallio MR, Oliviero C, Ahokas S, Peltoniemi OA: Comparison of azaperone-detomidine-butorphanol-ketamine and azaperone-tiletamine-zolazepam for anaesthesia in piglets. Vet Anaesth Analg. 2009 Mar;36(2):151-7. doi: 10.1111/j.1467-2995.2008.00443.x.
  • PMID: 3322780
    Duverger-van Bogaert M, Vanparys P, de Meester C, Marsboom R: Mutagenicity evaluation of azaperone in the Salmonella/microsome test. Drug Chem Toxicol. 1987;10(3-4):329-38.
Menampilkan 8 dari 31 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Stresnil

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul